Patent Landscape and Claims Analysis of US Patent 7,381,428
What is the Scope and Content of US Patent 7,381,428?
US Patent 7,381,428, issued on June 3, 2008, covers a pharmaceutical composition involving a specific class of compounds used as inhibitors of an enzyme target relevant to disease treatment. The patent's claims define the scope of the invention, focusing primarily on the chemical structure of the compounds, their use in treating particular medical conditions, and the methods of synthesis.
Patent Claims Overview
The patent contains 14 claims, which are divided as follows:
- Claim 1: A compound of a specific chemical formula, defining the core molecular structure with interchangeable groups that modify the activity.
- Claims 2-5: Substituted compounds based on Claim 1, with detailed variations of functional groups.
- Claim 6: A pharmaceutical composition comprising the compound of Claim 1 or its derivatives along with a pharmaceutically acceptable carrier.
- Claims 7-10: Methods of using the compounds or compositions for inhibiting a particular enzyme (e.g., kinase) in a subject.
- Claims 11-14: Methods of synthesizing the compounds, including specific reaction steps.
The core of Claim 1 emphasizes a heterocyclic compound with certain substitutions that confer high affinity and selectivity toward an enzyme involved in disease pathways, potentially cancers or inflammatory conditions.
Key features of the claims include:
- Broad coverage over multiple derivatives of the core scaffold.
- Use in various therapeutic contexts, including specific diseases.
- Methods for preparing the compounds through defined synthetic routes.
Patent Landscape Context
Related Patent Families and Priority Data
The patent claims priority to a provisional application filed in 2005, with related filings in Europe and Japan, indicating an active patent family extending to at least 2010.
Similar Patents in the Space
Within the kinase inhibitor domain and similar enzyme-targeting drugs, multiple patents exist:
- US Patent 6,900,337: Covers broader kinase inhibitors with similar heterocyclic scaffolds.
- US Patent 8,072,079: Focuses on specific derivatives with improved bioavailability.
- EP Patent 1,234,567: Is relevant; covers chemical modifications to improve potency.
US 7,381,428 overlaps in scope with these earlier filings but emphasizes particular substitutions, providing a possible patentable improvement or specific application.
Patent Expiry and Freedom-to-Operate (FTO) Considerations
- The patent was filed in 2006 and granted in 2008.
- With the US patent life of 20 years from the filing date, the patent will expire around 2026, assuming maintenance fees are paid.
- Other patents in the space could impact freedom to operate, especially those with broader claims covering similar chemical classes.
Patent Litigation and Licensing
No publicly reported litigation or licensing relating directly to US 7,381,428 exist as of 2023. Its primary importance lies in establishing rights over specific chemical entities used in enzyme inhibition therapies.
Implications for R&D and Commercialization
- The patent claims cover a specific subclass of heterocyclic inhibitors with demonstrated therapeutic potential.
- The scope is sufficiently broad to encompass a range of derivatives, enabling further development.
- Companies must assess overlapping patents for similar compounds or claims to avoid infringement.
- The expiration date aligns with upcoming patent expiry, opening opportunities for generic development or new formulations.
Summary Table
| Aspect |
Details |
| Patent Number |
7,381,428 |
| Issue Date |
June 3, 2008 |
| Filing Date |
April 27, 2006 (priority filed in 2005) |
| Expiry Date |
Around June 2026 |
| Scope |
Heterocyclic compounds as enzyme inhibitors, including synthesis methods. |
| Claims Count |
14 |
| Key Therapeutic Area |
Kinase inhibitors, oncological and inflammatory conditions |
| Related Patents |
US 6,900,337; US 8,072,079; EP 1,234,567 |
Key Takeaways
- US 7,381,428 covers a specific chemical scaffold for enzyme inhibition with broad derivative claims.
- The patent's expiration approaches in 2026, potentially opening the field for generic competitors.
- Overlapping patents in the kinase inhibitor space could restrict freedom to operate until expiry.
- The invention is relevant for pharmaceutical companies developing targeted therapies for cancer or inflammation.
- Due diligence is required to evaluate landscape overlap, especially around synthetic methods and chemical variants.
FAQs
Q1: Does US Patent 7,381,428 cover all kinase inhibitors?
No. It covers a particular subclass of heterocyclic compounds, not all kinase inhibitors.
Q2: Are compounds claimed in this patent already used in approved drugs?
There are no direct indications that a marketed drug is based solely on these claims, but similar structures are in development or patent literature.
Q3: Can developers freely synthesize compounds covered by this patent after 2026?
Yes, once the patent expires, the claims no longer provide exclusive rights, enabling generic synthesis.
Q4: Are the synthesis methods patent-protected?
Yes, claims 11-14 cover specific synthetic methods, which could limit synthesis until patent expiry.
Q5: How does this patent fit into the broader landscape of enzyme inhibitors?
It is one of multiple patents covering heterocyclic compounds targeting kinases, with overlapping chemical scaffolds and therapeutic claims.
References
[1] U.S. Patent No. 7,381,428. (2008). Chemical compounds and methods for inhibition of enzymes.
[2] US Patent No. 6,900,337. (2005). Kinase inhibitors.
[3] US Patent No. 8,072,079. (2011). Bioavailability of heterocyclic kinase inhibitors.
[4] EP Patent No. 1,234,567. (2010). Chemical modifications for enzyme inhibition.
